

This is a repository copy of Rasch Analysis of the Psoriatic Arthritis Quality of Life and Dermatology Life Quality Index Measures in Psoriatic Arthritis.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/88221/

Version: Supplemental Material

Proceedings Paper:

Ndosi, ME, Hsu, MA, Cappelleri, C et al. (3 more authors) (2015) Rasch Analysis of the Psoriatic Arthritis Quality of Life and Dermatology Life Quality Index Measures in Psoriatic Arthritis. In: Journal of Investigative Dermatology. 4th World Psoriasis & Psoriatic Arthritis Conference 2015, 08-11 Jul 2015, Stockholm Waterfront Congress Center, Stockholm, Sweden. Nature Publishing Group .

https://doi.org/10.1038/jid.2015.247

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/



Leeds Institute of Rheumatic and Musculoskeletal Medicine

UNIVERSITY OF LEEDS

Rasch Analysis of the Psoriatic Arthritis Quality of Life and Dermatology Life Quality Index Measures in Psoriatic Arthritis

Mwidimi Ndosi,¹ Ming-Ann Hsu,² Joseph C. Cappelleri,² Heather Jones,³ Amit Chhabra,⁴ Phillip Helliwell¹

¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, ²Pfizer Inc. Groton, CT, USA, ³Pfizer Inc. Collegeville, PA, USA, ⁴Pfizer Inc. New York, NY, USA





Psoriatic Arthritis Quality of Life (PsAQol) and Dermatology Life Quality Index (DLQI) measures cover different aspects of health-related quality of life (HRQOL) in people with psoriatic arthritis (PsA). There is uncertainty about the ability of each instrument to capture HRQOL information about skin and joint disease simultaneously.

Objectives

- I. To assess the validity of the PsAQoL and DLQI in people with PsA and to determine their invariance to different sub-groups of including culture.
- To determine if the two measures can capture HRQoL domains relevant to 11. both skin and joints in people with PsA.

Patients

Patients diagnosed with PsA recruited into GRACE project.¹ GRACE was a longitudinal observational study carried out over 15 countries in Europe, N America, S America and Asia. PsAQoL and DLQI data from baseline visit was used, including: age, gender, disease duration, disease type (oligo/polyarthritis), extent of skin involvement (Psoriatic Area Severity Index - PASI score).

Analysis

Rasch analysis² was used to assess the validity, reliability, and invariance of the tools to different subgroups of patients. Coverage was defined by targeting and the ability to discriminate between patients with different degrees of disease severity. Rasch analyses were undertaken using RUMM 2030 software.³

Results

Patient characteristics	Fit to the Rasch Model						Invariance		
Total of 503 patients with PsA diagnosis (by a physician)	Region		PsAQoL		DLQI		 PSAQoL No cross-cultural bias in the countries combined within a region (e.g. America = USA + Canada) 		
 Male = 287, female = 217 		Ν	χ2 interaction (p)	PSI	χ2 interaction (p)	PSI	 There was not enough data to reliably assess the degree of cross-culturation 		
 Mean age = 50.8 years, SD = 13.1, Description at heitig duration reason = 0.8 years, SD = 0.0 	UK	66	38.4812 (0.008)	0.870	14.227 (0.163)	0.819	 (regional) biases which are likely to be present Within each region (cultural group), there was no significant bias by 		
 Psoriatic arthritis duration, mean = 9.8 years, SD = 9.9 Psoriasis duration, mean = 18.4 years, SD = 13.7 	N America	83	25.3853 (0.187)	0.887	15.6375 (0.111)	0.781	gender, age, disease subtype (oligo/polyarthritis), disease duration or		
 Psoriasis area and severity index (PASI), mean = 4.2, SD = 6.5 	Europe	132	56.8823 (0.040)	0.826	24.221 (0.007)	0.825	degree of skin involvement (PASI cut-off point of 10)		
	S America	45	29.2163 (0.084)	0.800	30.854 (0.001)	0.803	 DLQI No cross-cultural bias in the countries combined within a region 		
	Asia	27	108.359 (0.978)	0.868	14.894 (0.136)	0.841	 There were gender biases on items 8 & 9 		
	Pooled	353	202.392 (<0.001)	0.851	167.741 (<0.001)	0.803	8. Over the last week, how much has your skin created problems with your partner or any of you close friends or relatives?		

Persons with

impaired HRQoL

not targeted by

the items

P	sA	QoL						
PERSONS				(Grou		hreshold I ength of 0.20		
	30 -	Level Poly	No. [64]	Mean 0.189 -1.977	SD 2.17	 		
F	25 -	Oligo	[53]	-1.977	1.78	 		
e q	20 -					 	/	Pers
u e	15 -					 		- impai


ITEMS


p > 0.05 for $\chi 2$ suggests fit to the model, PSI = Person Separation Index reliability

Coverage of Joint Domain of HRQoL

No full coverage as some persons with severe HRQoL were not targeted by the items. However, DLQI was better than PsAQoL at targeting and discriminating between persons with oligoarthritis vs. those with polyarthritis


- 9. Over the last week, how much has your skin caused any sexual difficulties?





Coverage of Skin Domain of HRQoL

No full coverage, as some persons with severe HRQoL were not covered by the items. DLQI was however better than PsAQoL at targeting discriminating between persons with mild skin disease (PASI </=10) vs. those with severe skin involvement (PASI >10)



Conclusion



- There is not enough evidence from this analysis to suggest the cross-cultural validity of the PsAQoL and DLQI
- There is not enough evidence to suggest whether each measure captures fully the HRQoL domains that are relevant to both skin and joints. PsQoL and DLQI appear to complement each other in capturing both joint and skin domains of HRQoL in people with PsA.
- Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(6):986-91.
- Rasch G. Probabilistic models for some intelligence and attainment tests. Chicago: University of Chicago; 1960.
- Andrich D, Sheridan B, Luo G. Rumm 2030: Rasch Unidimensional Measurement Models [computer software]. Perth: RUMM Laboratory; 2010.

This study was funded by Pfizer